Zelira Therapeutics Limited (ASX: ZLD) - Share Price
- Current share price for ZLD : $0.500
Zelira Therapeutics Limited (ZLD), an ASX-listed company, is a biopharmaceutical company in the research, development, and commercialization of cannabinoid-based medicines. The company owns a portfolio of products and a pipeline of candidates undergoing development positioned to enter markets. It is focused on developing and validating cannabinoid-based medicines in its prescription (Rx) business for the treatment of medical conditions including insomnia, autism, and chronic non-cancer pain, as well as offering over the counter (OTC) products.Zelira Therapeutics Limited (ZLD) is a biopharmaceutical company in the research, development, and commercialization of cannabinoid-based medicines. The company owns a portfolio of products and a pipeline of candidates undergoing development positioned to enter markets. It is focused on developing and validating cannabinoid-based medicines in its prescription (Rx) business for the treatment of medical conditions including insomnia, autism, and chronic non-cancer pain, as well as offering over the counter (OTC) products.
ZLD General Information +
| ASX Code | ZLD |
| Website | http://www.zeliratx.com |
| Industry/Sector | Pharmaceuticals |
| Market Cap ($M) | 5 |
| ZLD Share Price | $0.500 |
| Day High | $0.000 |
| Day Low | $0.000 |
| Last Close | $0.500 |
| ZLD Share Price Movement | - ( No change ) |
Prices as at 16:40, 22 Jun 2026
+Security prices are delayed by at least 20 minutes and are indicative only.
Zelira Therapeutics Limited (ZLD) Upcoming Dividends & Yields
| Distribution Type | Dividend | Franking | Ex-dividend date | Payment date | Current Price+ | Price 7D Avg | Dividend Yield |
|---|
See all dividends from Zelira Therapeutics Limited (ZLD) or use our Upcoming Dividends tool to search for dividends across all ASX-listed securities.
Zelira Therapeutics Limited (ZLD) price-sensitive announcements
ZLD - Quarterly Activities/Appendix 4C Cash Flow Report
Zelira Therapeutics Limited reported its quarterly activities and Appendix 4C cash flow fo
Zelira Therapeutics Limited (ZLD)
29 Jan 2026 | 9:25 AM
29 Jan 2026 | 9:25 AM
ZLD - Transformative US$33M Fundraising into Zeliras HOPE 1 SPV
Zelira Therapeutics Limited has announced a transformative fundraising of US$33 million in
Zelira Therapeutics Limited (ZLD)
16 Jan 2026 | 10:03 AM
16 Jan 2026 | 10:03 AM
ZLD - Zelira receives $1,070,000 R&D Tax Incentive Scheme Refund
Zelira Therapeutics Limited, a leading global biopharmaceutical company specializing in ca
Zelira Therapeutics Limited (ZLD)
25 Nov 2025 | 2:33 PM
25 Nov 2025 | 2:33 PM
ZLD - Quarterly Activities/Appendix 4C Cash Flow Report
Zelira Therapeutics Limited continues to advance its clinical development and commercializ
Zelira Therapeutics Limited (ZLD)
27 Oct 2025 | 2:33 PM
27 Oct 2025 | 2:33 PM
Zelira Therapeutics Limited (ZLD) Recent ASX Announcements
ZLD Financial Summary
| Year to Jun | NPAT | EPS | EPS chg (%) | PER | DPS | Yield (%) | Franking (%) |
|---|---|---|---|---|---|---|---|
| 2025A | -$3.85 | -$31.60 | -38.40% | 0.00 | 0.00 | 0.00% | 0.0% |
| 2024A | -$5.99 | -$51.30 | -11.30% | 0.00 | 0.00 | 0.00% | 0.0% |
| 2023A | -$6.52 | -$57.80 | -61.10% | 0.00 | 0.00 | 0.00% | 0.0% |
ZLD Peer Comparison
| Company | Mkt Cap | EPS Growth (%) | P/E (%) | Dividend Yield (%) | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 2023 A | 2024 A | 2025 A | 2023 A | 2024 A | 2025 A | 2023 A | 2024 A | 2025 A | ||
| Clarity Pharmaceuticals Ltd (CU6) | $817M | 0.3002 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.00% | 0.00% | 0.00% |
| Neuren Pharmaceuticals Limited (NEU) | $1,674M | -0.7857 | 0.0743 | 1.2000 | 56.9403 | 53.0000 | 24.0909 | 0.00% | 0.00% | 0.00% |
| Zelira Therapeutics Limited (ZLD) | $6M | -0.3843 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.00% | 0.00% | 0.00% |
ZLD Market Comparison
| Earnings | P/E Ratio | P/B Ratio | P/E Growth | |
|---|---|---|---|---|
| Company | 0.00 | 0.00 | -1.33 | 0.00 |
| Market | 0.29 | 13.20 | 1.17 | 0.67 |
| Sector | 0.43 | 26.00 | 2.55 | 2.41 |
ZLD Directors
| Name | Position | Start Date |
|---|---|---|
| Mr Timothy (Tim) Ryan Slate | Company Secretary, Non-Executive Director | 31 Jan 2022 |
| Mr Greg Blake | Executive Director | 20 Feb 2023 |
| Dr Oludare Odumosu | Managing Director | 4 Dec 2019 |
| Mr Osagie Imasogie | Non-Executive Chairman, Non-Executive Director | 4 Dec 2019 |
| Dr Donna Gentile O'Donnell | Non-Executive Director | 1 Jun 2023 |
Zelira Therapeutics Limited (ZLD) Changes in Directors' Interest & Trades
| Date of change | Director | Buy/Sell | Security Type | Qty | Trade Price | Value |
|---|---|---|---|---|---|---|
| 4 Dec 2025 | ODUMOSU, Oludare | Issued | Convertibles | 386,847 | $0.259 | $100,000.000 |
| 4 Dec 2025 | O'DONNELL, Donna | Issued | Convertibles | 193,423 | $0.259 | $50,000.000 |
| 13 Dec 2024 | IMASOGIE, Osagie | Issued | Convertibles | 3,500,000 | $0.400 | $1,400,000.000 |
See all changes in directors' interest & trades for Zelira Therapeutics Limited (ZLD) or use our Changes in directors' interest tool to search for changes & trades across all ASX-listed securities.
ZLD Substantial Shareholders
Under ASX rules large investors and investment funds must disclose when they own more than a 5% stake in Zelira Therapeutics Limited (ZLD). However, you won't necessarily see their names in the company’s annual report, as many trade under nominee names. These shareholders are obliged to provide ongoing substantial notices relating to any change of 1% or more.
| Holding | Name |
|---|---|
| 0 (0%) | Malik Majeed |
ZLD Calendar of Events
| Date | Event |
|---|---|
| 25 September 2026 | Report (Annual) |
| 28 August 2026 | Report (Prelim) |
DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.
Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate,
complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892)
and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and,
if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest.
No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser.
Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.
What our members say about us
Proudly
We're here to help
Call 1300 880 160
Start a chat
Schedule a call
